Dear Editor:

A 57-year-old woman with a history of hypertension and breast cancer in complete remission was seen in late-March 2020 at the emergency ward in a private clinic with dry cough, anosmia, and dysgeusia. Physical examination found a low grade fever (37.8 °C) but was otherwise normal. A thoracic computerized tomography was normal, and a single nasopharyngeal swab (NPS) was reported as negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by a polymerase chain reaction (PCR)--based test. A complete blood work-up was normal except for mild lymphopenia (Day 1 on Table [1](#Tab1){ref-type="table"}).Table 1Evolution of laboratory findings from the day of onset until end of plasma exchange therapyLaboratory testDay 1Day 6Day 8Day 9 (before plasma infusion)Day 10 (after plasma infusion)Day 17 (after 7 days of plasma exchange)Hb (g/L) (NV 120--150)1309983696497Platelets (× 10E9/L) (NV 140--350)19122231386220Leukocyte count (× 10E9/L) (NV 3.80--11.00)4.785.3117.4020.3312.359.03Lymphocyte count (× 10E9/L (%)) (NV 1.00--4.00)0.57 (12)1.61 (30.3)1.04 (6)3.05 (15)2.45 (19.8)2.17 (24)Reticulocyte count (× 10E9/L (%)) (NV 20--100 (0.5--2))\--69 (-)69.8 (3.05)155.4 (7.73)130.9 (4.35)Schistocyte count (%) (NV \< 0.5)\-\--610-Creatinine (mg/L) (NV 0.6--1.2)0.800.800.680.720.680.61LDH (U/L) (NV 125--243)267145123151594950218Indirect bilirubin (mg/dL) (NV 0.3--1.0)-1.951.460.86\--CRP (mg/L) (NV \< 5.0)4339.8011.605.86.6\< 1.0ADAMTS-13 (%) (NV \> 70%)\-\--21.9189ADAMTS-13 inhibitor (NV negative or \< 0.4 Bethesda units)\-\--Positive (5.2 Bethesda units)-Positive (2.5 Bethesda units)- refers to non-available tests*NV* normal values, *CRP* C-reactive protein

Because of the pandemic state of SARS-CoV-2 and associated symptoms \[[@CR1]\], the treating physicians considered the patient to have coronavirus disease 2019 (COVID-19) but with a false-negative result of the PCR NPS test. The patient was treated with lopinavir/ritonavir, hydroxychloroquine, and azithromycin. On the fifth day of treatment (Day 6 on Table [1](#Tab1){ref-type="table"}) routine blood tests showed severe thrombocytopenia, moderate anemia with a normal reticulocyte count, and high serum lactate dehydrogenase (LDH) and bilirubin (Table [1](#Tab1){ref-type="table"}). Treatment with methylprednisolone 1 mg/kg/24 h and intravenous immunoglobulin was added, but after no improvement in laboratory findings (Day 8 on Table [1](#Tab1){ref-type="table"}), the patient was transferred to our institution for further management.

After initial clinical and laboratory work-up at our institution (Day 9 on Table [1](#Tab1){ref-type="table"}), a diagnosis of autoimmune thrombotic thrombocytopenic purpura (TTP) was rapidly established, based on the presence of microangiopathic hemolytic anemia, severe thrombocytopenia, and very low activity (2%) of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in combination with the presence of an ADAMTS-13 inhibitor, which is an autoantibody to ADAMTS-13 \[[@CR2], [@CR3]\].

A NPS sample was retested in our center on admission and was negative for SARS-CoV-2, but serological tests were positive for SARS-CoV-2 IgG, thus confirming the past COVID-19 \[[@CR4]\].

Treatment with plasma infusion on admission led to a rapid rise in the patient's platelet count (Day 10 on Table [1](#Tab1){ref-type="table"}). After placement of a central venous catheter, therapeutic plasma exchange was begun, with a favorable clinical and laboratory course over the next week (Day 17 on Table [1](#Tab1){ref-type="table"}).

We present a case of acquired autoimmune TTP whose onset occurred immediately after COVID-19, since the patient was admitted for this latter infection with normal laboratory values.

Of course, this could be a mere coincidence rather than a causal relationship, owing to the very high incidence of SARS-CoV-2 infection \[[@CR5]\].

As with other hematological disorders, the COVID-19 pandemic may change the way in which the approach to and management of patients may vary from the standard of care, as highlighted by the American Society of Hematology COVID-19 Resources Center (specific information on TTP can be found at [[https://www.hematology.org/covid-19/covid-19-and-ttp]{.ul}](https://www.hematology.org/covid-19/covid-19-and-ttp)).
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